Please login to the form below

Not currently logged in
Email:
Password:

reimbursement models

This page shows the latest reimbursement models news and features for those working in and with pharma, biotech and healthcare.

UK to cut wait to innovative treatments by four years

UK to cut wait to innovative treatments by four years

The pathway would better align the current regulatory, reimbursement, evaluation and diffusion processes, and provide companies with tailored support in navigating the new, simplified system. ... Chief executive of NHS England Simon Stevens pledged that

Latest news

  • The Digital Patient The Digital Patient

    There is a high consumer demand for mHealth apps, it says, but monetising them is difficult due to a lack of clear reimbursement models, particularly in the NHS.

  • The Italian Job The Italian Job

    Therapy efficacy and value-based reimbursement models. In my August column in this publication, I spoke about the need for establishing a mechanism that would allow stakeholders to gain some sort ... Express Scripts will launch a new value-based

  • Realising the potential of cell therapies Realising the potential of cell therapies

    The CTC provides advice on business models, manufacturing, health economics and reimbursement considerations, for example, to try to make sure that there is someone to pay the bill for a new ... To achieve that objective the sector will need the

  • Technology trends facing pharma in 2013 Technology trends facing pharma in 2013

    This data explosion is also providing opportunities for companies to develop new, real-world data analytic capabilities which can enable new business services and reimbursement models, for example by linking patient ... Linking this information can put

  • Are we running fast enough?

    Developing complex value propositions should place pricing and reimbursement at the heart of early commercialisation efforts, alongside thought leader engagement and clinical trial planning, but such moves are not yet widely ... The emergence of risk

More from news
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • No incentive for a cure No incentive for a cure

    and Scandinavia. Each of the different models are variations of a fee-for-service reimbursement model, which have evolved to meet the needs of chronic illnesses. ... Incremental changes may work in the short-term. Incremental changes include solutions

  • Lighting the way Lighting the way

    This pathway would better align the current regulatory, reimbursement, evaluation and diffusion processes, and provide companies with tailored support in navigating the new, simplified system. ... reimbursement models” for greater patient access.

  • Market access improvements in Turkey Market access improvements in Turkey

    In 2015 there were 8, 104 products on the reimbursement list, with 292 new ones added. ... company. Alternative reimbursement models. The SGK was first authorised in September 2014 to develop 'alternative reimbursement models' as a new channel through

  • Managing real world data governance Managing real world data governance

    These emerging regulatory and reimbursement models all aim to make treatment provision and access more sensitive to the evolving evidence base, and all require RWD. ... models. Where the appropriate safeguards are in place, authorisation should be based

  • Turkey: A growing pharma market with huge potential Turkey: A growing pharma market with huge potential

    With the recent enactment of Law 6552, the Social Security Institution has been authorised to develop alternative reimbursement models. ... Although these alternative reimbursement models can provide a way out, without objective reimbursement

More from intelligence
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics